Sialorrhea
21
0
1
14
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
24%
5 trials in Phase 3/4
43%
6 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (21)
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Effect of SCS Technique on Oromotor Skills in Children With CP
Pharmacokinetics of Atropine Oral Gel
Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects
Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Prevalence of Sialorrhea in Patients Treated With Clozapine
Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders
Ipratropium Bromide Spray as Treatment for Sialorrhea in Children
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
Clozapine-induced Hypersalivation - Feasibility Trial
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases
Oral Health Literacy Tailored Communication
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)